Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Cure rate for L braziliensis bolivian CL has been 70%-80% for standard systemic and local
monotherapies. It would benefit patients if cure rates could be consistently >90%, so testing
a combination of two treatments is proposed. The most attractive systemic therapy is the only
oral agent, miltefosine during 28 days, and the most attractive local therapy is application
of Paromomycin cream for 28 days.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fundacion Nacional de Dermatologia
Collaborators:
Alfred Berman Foundation Hospital Dermatológico de Jorochito Ministerio de Salud de Bolivia, Programa Nacional de Leishmaniasis